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BACKGROUND
Charcot–Marie–Tooth neuropathy has been reported to be associated with renal 
diseases, mostly focal segmental glomerulosclerosis (FSGS). However, the common 
mechanisms underlying the neuropathy and FSGS remain unknown. Mutations in 
INF2 were recently identified in patients with autosomal dominant FSGS. INF2 en-
codes a formin protein that interacts with the Rho-GTPase CDC42 and myelin and 
lymphocyte protein (MAL) that are implicated in essential steps of myelination and 
myelin maintenance. We therefore hypothesized that INF2 may be responsible for 
cases of Charcot–Marie–Tooth neuropathy associated with FSGS.
METHODS
We performed direct genotyping of INF2 in 16 index patients with Charcot–Marie–
Tooth neuropathy and FSGS who did not have a mutation in PMP22 or MPZ, encoding 
peripheral myelin protein 22 and myelin protein zero, respectively. Histologic and 
functional studies were also conducted.
RESULTS
We identified nine new heterozygous mutations in 12 of the 16 index patients (75%), 
all located in exons 2 and 3, encoding the diaphanous-inhibitory domain of INF2. 
Patients presented with an intermediate form of Charcot–Marie–Tooth neuropathy as 
well as a glomerulopathy with FSGS on kidney biopsy. Immunohistochemical analy-
sis revealed strong INF2 expression in Schwann-cell cytoplasm and podocytes. 
Moreover, we demonstrated that INF2 colocalizes and interacts with MAL in Schwann 
cells. The INF2 mutants perturbed the INF2–MAL–CDC42 pathway, resulting in cy-
toskeleton disorganization, enhanced INF2 binding to CDC42 and mislocalization of 
INF2, MAL, and CDC42.
CONCLUSIONS
INF2 mutations appear to cause many cases of FSGS-associated Charcot–Marie–Tooth 
neuropathy, showing that INF2 is involved in a disease affecting both the kidney glom-
erulus and the peripheral nervous system. These findings provide new insights into 
the pathophysiological mechanisms linking formin proteins to podocyte and Schwann-
cell function. (Funded by the Agence Nationale de la Recherche and others.)
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Charcot–Marie–Tooth disease refers to a heterogeneous group of inherited chronic peripheral motor and sensory neu-
ropathies.1 Affected persons typically present with 
progressive distal-muscle weakness and atrophy, 
reduced tendon reflexes, and foot and hand defor-
mities. Three Charcot–Marie–Tooth disease sub-
types have been distinguished by means of elec-
trophysiological and neuropathological studies 
— a glial myelinopathy (type 1) characterized by 
slow motor-nerve conduction velocities and demy-
elinating neuropathy, an axonal form (type 2) as-
sociated with normal or subnormal nerve conduc-
tion velocities and axonal degeneration, and an 
intermediate form with demyelinating and axonal 
features in which patients from the same family 
may have either subnormal or reduced nerve con-
duction velocities.2 At least 40 different genes or 
loci have been associated with this disease (as has 
been reviewed by Lupski and colleagues).3 Auto-
somal dominant Charcot–Marie–Tooth type 1 is the 
most prevalent form, with mutations in the periph-
eral myelin protein 22 gene (PMP22) and the myelin 
protein zero gene (MPZ) underlying most cases.4,5
An increased prevalence of nephropathies, par-
ticularly focal segmental glomerulosclerosis (FSGS), 
has been documented in patients with Charcot–
Marie–Tooth neuropathy,6 but the pathophysiologi-
cal mechanism linking these two clinical entities 
is unknown. FSGS is a histologic pattern of renal 
damage that is associated with a spectrum of pri-
mary and secondary glomerular diseases, includ-
ing isolated proteinuria and glucocorticoid-resis-
tant nephrotic syndrome.7 In the past few years, 
the identification of genes involved in hereditary 
glomerulopathies has expanded knowledge about 
the crucial role of the podocyte, a glomerular epi-
thelial cell with interdigitating foot processes, as 
well as its actin cytoskeleton, in the function of the 
glomerular filtration barrier.8
INF2 mutations account for 12 to 17% of auto-
somal dominant cases of FSGS.9,10 The gene en-
codes a member of the diaphanous-related formin 
family, which is involved in remodeling the actin 
and microtubule cytoskeletons.11 INF2 possesses 
functional domains characteristic of other diaph-
anous-related formins: an N-terminal diaphanous-
inhibitory domain (DID), the formin homology 
domains FH1 and FH2, and a C-terminal diaph-
anous-autoregulatory domain (DAD).11 However, 
INF2 has a unique ability to promote not only 
actin polymerization but also filament severing 
and depolymerization.12
INF2 interacts with other diaphanous-related 
formins, such as mDia1–DIAPH113 and the Rho-
GTPase CDC42,14,15 through its DID. In addition, 
it has been shown to bind (through its C-terminal) 
the myelin and lymphocyte protein (MAL) in Jurkat 
T cells15 and MAL2 in Madin–Darby canine kidney 
cells and HepG2 hepatocytes14 to regulate intracel-
lular protein transport.14-16 Although very little 
is known about the role of diaphanous-related 
formins in the peripheral nervous system, the im-
plication of CDC4217 and MAL18 in essential steps 
of myelination and myelin maintenance led us to 
hypothesize that INF2 mutations may be responsi-
ble for the association between FSGS and Charcot–
Marie–Tooth neuropathy.
Me thods
Study Participants
The study was conducted from March 2010 through 
September 2011. Sixteen index patients (seven with 
apparent autosomal dominant inheritance and nine 
with sporadic disease) from 16 unrelated families 
were included in the study. Twelve were from our 
French FSGS DNA cohort, including 2 families 
described previously.19,20 We contacted authors 
of published cases of FSGS and Charcot–Marie–
Tooth neuropathy 6,21 and thereby obtained DNA 
samples from 4 additional families. Twenty-five 
members of the patients’ families were also tested. 
All index patients presented with clinical mani-
festations of Charcot–Marie–Tooth disease asso-
ciated with FSGS. The index patients had all been 
diagnosed with Charcot–Marie–Tooth disease by 
a neurologist in their primary care centers on the 
basis of their clinical history, physical examina-
tion, and electrophysiological or histologic test-
ing. Mutations in PMP22 or MPZ were ruled out in 
all patients. Written informed consent was ob-
tained from all study participants or their par-
ents, and the study was approved by the Comité 
de Protection des Personnes Ile-De-France II.
Genetic, Histologic, and Functional Studies
INF2 exons 2, 3, and 4 were sequenced for all par-
ticipants, and in the absence of mutations, the re-
maining exons were sequenced (as previously de-
scribed10). Localization of INF2, MAL, and MAL2 
in normal human kidney and peripheral-nerve 
specimens and in cultured Schwann cells was as-
sessed by means of immunoperoxidase and immu-
nofluorescence staining. The interaction of INF2 
with MAL in Schwann cells was demonstrated by 
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pull-down assay. The effects of INF2 mutant ex-
pression on interaction with active CDC42 and 
IQGAP1 were evaluated by coimmunoprecipitation, 
and the effects of INF2 mutant expression on in-
tracellular localization of MAL and CDC42 and on 
the actin cytoskeleton were evaluated by immuno-
fluorescence. Two INF2 mutants associated with 
FSGS and Charcot–Marie–Tooth neuropathy and 
three INF2 mutants associated with FSGS were 
studied. A detailed description of the methods used 
is provided in the Supplementary Appendix, avail-
able with the full text of the article at NEJM.org.
R esult s
INF2 Mutations
Heterozygous INF2 mutations were detected in 
12 of the 16 index patients (75%). Nine different 
mutations were identified: eight missense muta-
tions and one in-frame deletion of three amino ac-
ids. All were new mutations located in exons 2 and 
3, which encode the DID domain (Fig. 1A, and 
Table 1S in the Supplementary Appendix), and all 
caused nonconservative changes in highly con-
served amino acids. Scores from PolyPhen-2 soft-
ware analysis (http://genetics.bwh.harvard.edu/
pph2) to predict the functional effects of mis-
sense INF2 variants ranged from 0.993 to 1, pre-
dicting that INF2 variants were probably damag-
ing. No INF2 variants were present in any of the 
670 control chromosomes assayed or referenced 
in the National Heart, Lung, and Blood Institute’s 
Figure 1. Summary of INF2 Substitutions in the 12 Study 
Patients.
Panel A shows substitutions identified in the study pa-
tients (red, in Panels A and B) as well as those found 
in previous studies of focal segmental glomeruloscle-
rosis (FSGS) alone (green, in Panels A and B), aligned 
with the C-terminal sequence (indicated with the string 
of single-letter amino acid symbols) of human, mouse, 
and xenopus INF2 proteins, opossum INF2-like pro-
tein, and human and mouse DIAPH1 proteins. Resi-
dues important for the DID–DAD interaction22 are 
shown in blue or, if the residues were also altered in a 
patient presenting with FSGS and Charcot–Marie–
Tooth neuropathy, in purple (in Panels A and B). The 
numbering of amino acids from the translation initia-
tion site is shown to the right of each sequence, and 
armadillo repeats are shown to highlight the distinct 
localization of mutants associated with FSGS and 
Charcot–Marie–Tooth neuropathy and of mutants as-
sociated with FSGS alone. Panel B is a three-dimen-
sional representation of the N-terminal portion of  
human INF2 viewed from op-posing directions, con-
structed on the basis of the structure of mDia1. The 
residues associated with FSGS and Charcot–Marie–
Tooth neuropathy (red and purple) are located in the 
inner face of the central core of the DID, whereas the 
mutant residues responsible for FSGS only (green) are 
more externally located.
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Exome Sequencing Project server. Mutations seg-
regated with the disease in each familial case, 
although intrafamilial variability was noted (Fig. 
1S in the Supplementary Appendix). A de novo mu-
tation was confirmed in all three sporadic cases 
for which DNA was available from both parents 
of the patient. Most mutations identified in pa-
tients exhibiting FSGS and Charcot–Marie–Tooth 
neuropathy were localized in the 3′ end of exon 2 
and in exon 3, in which no mutation has been iden-
tified to date (to our knowledge). The INF2 vari-
ants were clustered between nucleotides 300 and 
500, whereas most isolated FSGS mutants were 
located downstream of nucleotide 500. To make 
functional predictions, we mapped mutants asso-
ciated with FSGS alone9,10 and those associated 
with FSGS and Charcot–Marie–Tooth neuropathy 
onto a human INF2 DID in silico model (Fig. 1B); 
although all involved DID residues, mutations 
in the two groups of patients were distinctly lo-
calized, the latter being located mostly in the 
second and third DID armadillo repeats and the 
former mostly in the fourth armadillo repeat 
(Fig. 1B).
To evaluate the potential role of INF2 in isolated 
Charcot–Marie–Tooth disease, we performed mu-
tational analysis of INF2 exons 2, 3, and 4 in an 
additional group of 50 patients who presented with 
Charcot–Marie–Tooth disease without a known 
renal phenotype, nerve conduction velocities in the 
intermediate range (25 to 45 m per second),2 and 
without any PMP22 duplication or deletion or MPZ 
mutation. No pathogenic mutation was identified 
in this group.
phenotype of patients with INF2 Mutations
The 12 index patients with INF2 mutations present-
ed with proteinuria at a median age of 18 years 
(range, 10 to 21), and end-stage renal disease 
(ESRD) developed in 11 patients at a median age 
of 21 years (range, 12 to 47) (Table 1). All patients 
exhibited lesions of FSGS (not otherwise speci-
fied)7 (Fig. 2A), but full-blown nephrotic syndrome 
was noted in only 5.
The neurologic phenotype of index cases is de-
tailed in Table 1 and in the Supplementary Appen-
dix. The median age at onset of peripheral-nerve 
dysfunction was 13 years (range, 5 to 28). Ten of 
the 12 index patients had moderate to severe symp-
toms at diagnosis, including walking difficulties 
and limited hand function, muscle wasting, and 
abolition of deep tendon reflexes in the lower and 
upper limbs. Four patients also had mild or mod-
erate sensorineural hearing loss. In addition, mag-
netic resonance imaging of the brain, performed 
in 2 patients (15 and 48 years old), showed central 
nervous system anomalies characterized by white-
matter hyperintensity and ventricular dilation, 
which were more severe in the older patient (Fig. 
2B). Median-nerve conduction velocities were in the 
range of intermediate Charcot–Marie–Tooth neu-
ropathy (23 to 45 m per second). Patient K.3 had 
almost normal median-nerve conduction velocities 
(45 m per second), whereas her maternal aunt had 
reduced velocities (30 m per second; data not 
shown). The six available sural-nerve biopsy spec-
imens all showed a pattern of lesions with a com-
bination of axonal and demyelinating changes, 
characterized by a marked decrease in myelinated 
fibers (Fig. 2C), as compared with that in age-
matched controls, and numerous multilayered “on-
ion bulbs” (Fig. 2D). Together, these data suggest 
an intermediate Charcot–Marie–Tooth phenotype 
in patients with INF2 mutations.
INF2 Expression in Podocytes  
and Schwann Cells
In peripheral nerves, we detected robust INF2 stain-
ing in Schwann cells and lighter staining in some 
axons (Fig. 3A, and Fig. 2S in the Supplementary 
Appendix). In the kidney, we confirmed that INF2 
expression occurs predominantly in podocytes. We 
detected weak staining in the proximal and distal 
tubules and found no INF2 in vessels. In kidney-
tissue and sural-nerve sections from the patients, 
INF2 staining persisted, but the severity of the le-
sions precluded our drawing any conclusion with 
respect to putative overexpression.
INF2 and MAL in Schwann Cells
MAL interacts with INF215 and is a major compo-
nent of myelin.18 We therefore hypothesized that 
mutant INF2 proteins could alter the INF2–MAL 
pathway in Schwann cells. We demonstrated the 
presence of INF2, together with MAL, in normal 
human peripheral-nerve serial sections and the 
endogenous colocalization of INF2 and MAL in 
mouse Schwann cells (Fig. 3A and 3B). Moreover, 
glutathione S-transferase–pull-down experiments 
revealed an interaction between the INF2 C-termi-
nal and endogenous MAL in Schwann cells (Fig. 
3C). We also confirmed INF2 and MAL2 localiza-
tion in human podocytes, and the absence of 
MAL in the glomeruli (Fig. 3A).
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We then investigated the effects of INF2 mu-
tants on MAL localization (Fig. 3D). In contrast 
to the perinuclear localization of the wild-type 
form of INF2,9,25 INF2 mutants in patients with 
FSGS and Charcot–Marie–Tooth disease were dif-
fusely localized throughout the cytoplasm, similar 
to the FSGS mutants studied here and by others.9
We also observed that MAL had a perinuclear 
localization when transfected alone or with the 
wild-type form of INF2, whereas its distribution 
was diffuse throughout the cell with INF2 mu-
tants, and that the two proteins were colocalized 
(Fig. 3C). Costaining of endogenous protein disul-
fide isomerase (PDI) confirmed the predominant 
localization of wild-type INF2 to the endoplasmic 
reticulum.25 In cells expressing INF2 mutants, the 
mislocalization of INF2 coincided with a diffuse 
pattern of PDI staining, which could reflect cy-
toskeleton disorganization (Fig. 3S in the Sup-
plementary Appendix).
C Decreased Myelinated Fibers in Sural Nerves
A FSGS-Related Lesions B Anomalies of the Central Nervous System
Control Patient J.3 Control Patient C.1 Patient A.3
Control Patient C.1 Patient F.3 Patient A.3
D Other Sural-Nerve Anomalies
Control Patient I.1 Patient H.1 Patient A.3
2 µm 2 µm
2 µm 2 µm 2 µm 1 µm 10 µm
50 µm 50 µm 50 µm
50 µm50 µm
2 µm
50 µm
Figure 2. Features on Pathological Analysis and Neuroimaging in Selected Patients with Focal Segmental Glomerulosclerosis (FSGS) 
and Charcot–Marie–Tooth Neuropathy.
Panel A shows the results of trichrome staining of kidney sections from a normal control and Patient J.3, who has typical lesions of FSGS 
not otherwise specified. Panel B shows the results of magnetic resonance imaging (MRI) of the brain (fluid-attenuated inversion recovery 
[FLAIR] sequences) of a normal control and two patients: one 15 years of age (Patient C.1) and the other 48 years of age (Patient A.3). 
Arrows point to bilateral symmetric hyperintensities visible in the internal capsule and the periventricular white matter. Panel C shows 
sural-nerve semithin sections revealing a marked loss of myelinated fibers in the patients (arrows). The severity of the lesions appears to 
increase with the patient’s age (from left to right, 15, 30, and 48 years); all myelinated fibers were absent in the oldest patient (Patient A.3). 
Panel D shows electron micrographs of sural-nerve sections revealing multilayered “onion bulbs” (in Patient I.1) and supernumerary 
elongated extensions from the cytoplasm of many nonmyelinating Schwann cells (in Patient H.1, arrows), occasionally including collagen 
fibers (in Patient H.1, arrowheads). In the oldest patient (Patient A.3), the endoneurium was completely replaced by numerous whorls of 
nonmyelinating Schwann-cell cytoplasm.
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INF2 Mutants and Actin cytoskeleton 
regulation
Cells expressing mutant INF2 exhibited less corti-
cal actin and a reduced number of long actin stress 
fibers than those expressing wild-type INF2, and 
a disorganized microtubule network (Fig. 4S, 5S, 
and 6S in the Supplementary Appendix). Similar 
features were observed with the K/A–3L/A–INF2 
mutant that lacks both the polymerization and de-
polymerization activities of wild-type INF2,14 al-
though with this mutant the decrease in the con-
tent of long actin filaments was less severe.
We therefore investigated whether the muta-
tions in INF2 proteins affect their binding to 
CDC42, an actin-regulating Rho-GTPase known to 
interact, in its GTP-loaded active state, with the 
INF2 DID.14 An enhanced interaction was observed 
between the INF2 mutants and a constitutively 
active form of CDC42 (CDC42-Q61L) as compared 
with the wild-type INF2 protein (Fig. 4A and 4B). 
Moreover, INF2 mutants affected the subcellular 
localization of CDC42-Q61L, with the fraction of 
active CDC42 at the plasma membrane being lost 
in a large proportion of mutant cells as compared 
with cells expressing wild-type INF2 (Fig. 4C), but 
did not significantly perturb CDC42 activity (Fig. 
7S in the Supplementary Appendix), a result con-
sistent with INF2 being a downstream target of 
CDC42.14,15 We also demonstrated the interaction 
of INF2 with IQGAP1, a CDC42 effector known to 
interact with mDia1.26,27 INF2 mutants still in-
teracted with IQGAP1 and altered the endogenous 
IQGAP1 subcellular distribution (Fig. 8S in the 
Supplementary Appendix), as they did for MAL 
and CDC42.
Discussion
We have demonstrated that, in addition to leading 
to isolated FSGS, INF2 mutations are a major cause 
of Charcot–Marie–Tooth disease associated with 
FSGS, accounting for approximately 75% of all cas-
es. These results shed new light on the genetic basis 
of the dual neurologic and renal phenotype first 
described by Lemieux and Neemeh in 1967.21
Since the initial description, several cases of 
renal involvement (mostly glomerular disorders 
with FSGS lesions) have been reported in associa-
tion with Charcot–Marie–Tooth disease.6 Plaisier 
and colleagues28 demonstrated the presence of 
myelin protein zero (MPZ) in podocytes and an 
increased urinary albumin excretion in Mpz knock-
out mice, indicating a potential role of myelin 
components in glomerular permselectivity. No 
PMP22 or MPZ mutation has been reported in pa-
tients with FSGS and Charcot–Marie–Tooth neu-
ropathy. In contrast, three quarters of the patients 
in the present study had INF2 mutations. None 
of these mutations were present in patients with 
Charcot–Marie–Tooth disease only, suggesting that 
INF2 is not involved in cases of the disease with-
out an apparent renal phenotype. Nevertheless, 
because of the individual and intrafamilial pheno-
typic variability we observed, physicians should 
be alert for proteinuria in all patients who have 
Charcot–Marie–Tooth disease. Similarly, pes cavus 
was the only clinical sign of Charcot–Marie–Tooth 
disease in some members of patients’ families; 
therefore, a careful clinical neurologic evaluation 
should be considered for patients with FSGS.
Although INF2 mutations have been shown to 
be the major cause of autosomal dominant isolated 
FSGS, accounting for 12 to 17% of all cases,9,10 
the prevalence of INF2 mutations in association 
with FSGS and Charcot–Marie–Tooth disease is 
much higher (75%). Several lines of genetic and 
functional evidence indicate that these variants 
are pathogenic mutations. Given the high preva-
lence of INF2 mutations, the detection of various 
distinct INF2 mutations, and the absence of muta-
tions in PMP22 and MPZ, the occurrence of a muta-
tion in another gene underlying Charcot–Marie–
Tooth disease in patients with INF2-related FSGS 
is unlikely. Moreover, it is improbable that the fre-
quent de novo mutations we detected would occur 
in two distinct genes in the same patient. Further-
more, all of the nine INF2 mutations we identified 
are new. Although the nine mutations encode DID 
residues, as do mutations associated with isolated 
FSGS, they had a distinct localization, correspond-
ing mostly to the 3′ end of exon 2 as well as in 
exon 3, in which no isolated FSGS mutation has 
been identified.
We further explored the functional effects of 
some INF2 mutations. We postulated that the 
mechanisms linking INF2 to the development of 
Charcot–Marie–Tooth disease involved perturba-
tion of cytoskeletal networks and thus intracellular 
transport of myelin components. Indeed, INF2 has 
been shown to regulate specialized routes of pro-
tein targeting to the plasma membrane in various 
types of cells in association with CDC42 and MAL 
or MAL2.14,15 This targeting involves vesicular car-
riers that associate with actin filaments and re-
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quires both the actin polymerization and depo-
lymerization properties of INF2.14,15 In addition, 
CDC42 and MAL are fundamental players in pe-
ripheral myelination.17,18,29 Here we show that 
INF2 is also expressed in Schwann cells and to a 
lesser extent in neurons. We also demonstrate the 
endogenous colocalization of INF2 and MAL and 
their in vivo interaction in Schwann cells, thereby 
providing a clear rationale for the role of INF2 mu-
tations in Charcot–Marie–Tooth disease. In addi-
tion, we show that INF2 mutations disrupt the 
INF2–MAL–CDC42 pathway. The reduction in cor-
tical actin and stress fibers in cells expressing 
INF2 DID mutants was even more severe than in 
cells expressing the K/A–3L/A–INF2 mutant lack-
ing both the polymerization and depolymerization 
properties of INF2. This suggests that INF2 DID 
mutants might not only alter these two functions 
but also have additional effects on INF2 partners. 
Indeed, we demonstrated an enhanced interaction 
between the INF2 DID mutants and CDC42 and a 
reduced fraction of active CDC42 at the plasma 
membrane. Together, our results suggest that the 
mislocalization of the INF2–MAL–CDC42 complex 
in the cytoplasm, as well as the defects in the po-
lymerization and depolymerization activities of 
INF2 required for actin dynamics, could disrupt 
protein targeting to the plasma membrane and 
therefore also disrupt proper myelin formation and 
maintenance.
The implication of the Rho-GTPase CDC42 
pathway in the effect of the INF2 mutants is remi-
niscent of mutations in two genes involved in 
dominant intermediate Charcot–Marie–Tooth dis-
ease: DNM2, which encodes the GTPase protein 
dynamin 2,30 and ARHGEF10, which encodes a gua-
nine exchange factor that activates Rho-GTPases.31
Finally, sensorineural hearing loss was present 
in 4 of the 12 families (33%) with an INF2 muta-
tion, which is a prevalence significantly higher 
than the approximately 5% prevalence reported 
among patients with Charcot–Marie–Tooth dis-
ease.32 Mutations in DIAPH1, which encodes 
mDia1, have been associated with autosomal 
dominant sensorineural progressive hearing loss.33 
The biologic role of mDia1 in hearing is likely to 
include regulation of actin polymerization in 
hair cells of the inner ear. Sun and colleagues13 
recently demonstrated that the INF2 DID interacts 
with the mDia1 DAD. Thus, similar mechanisms 
are likely to be involved in deafness related to ei-
ther DIAPH1 or INF2 mutations.
The reasons why INF2 mutations do not always 
lead to a neurologic phenotype still need to be 
clarified. One clue, however, is that the mutations 
underlying FSGS alone or in combination with 
Charcot–Marie–Tooth neuropathy are clustered in 
different parts of the DID. The latter mutations are 
located between two putative DID-binding pock-
ets, suggesting that they could affect DID function 
more severely than mutations related to FSGS 
alone, by simultaneously disrupting the interaction 
of INF2 with multiple proteins, some of which 
could be specific myelin proteins. This is consis-
tent with the renal phenotype that is more severe 
in patients with FSGS and Charcot–Marie–Tooth 
disease than in patients with FSGS (median age at 
Figure 3 (facing page). Colocalization and Interaction 
of Wild-Type and Mutant INF2 with Myelin and Lym-
phocyte Protein (MAL).
Panel A (immunoperoxidase stain) shows MAL, INF2, 
and MAL2 proteins in normal human kidney specimens 
and peripheral-nerve biopsy specimens. The serial sec-
tions shown suggest that INF2 colocalizes with MAL2 
in podocytes and MAL in Schwann cells. Panel B shows 
immunostaining of endogenous INF2 (green) and MAL 
(red) in MSC-80 mouse Schwann cells (with the merged 
image also shown).23 The scatter plot represents red 
and green pixel fluorescence intensities of the corre-
sponding immunostaining. Both proteins were colo-
calized (for eight samples analyzed: median Pearson’s 
coefficient, 0.909; range, 0.625 to 0.978).24 Panel C 
shows results of an INF2–MAL pull-down assay per-
formed on the detergent-insoluble (I) membrane fraction 
of S16 rat Schwann cells separated from the soluble 
fraction (S) and the Ponceau red staining of the gluta-
thione S-transferase proteins used at the bottom. In 
Schwann cells, endogenous MAL bound the C-terminal 
of INF2. Panel D shows the colabeling of wild-type or 
mutant FLAG-tagged INF2 (red) with myelocytomato-
sis virus–associated sequence (MYC)–tagged MAL 
(green) transiently expressed in HeLa cells, with the 
corresponding scatter plot of red and green pixel fluo-
rescence intensities on the right. In contrast to the peri-
nuclear localization of wild-type INF2, the two INF2 
mutants (with amino acid change L165P or R106P) in 
patients with focal segmental glomerulosclerosis 
(FSGS) and Charcot–Marie–Tooth (CMT) neuropathy 
were spread throughout the cytoplasm. As observed 
with endogenous proteins, wild-type INF2 and MAL re-
combinant proteins were colocalized (see merged im-
ages). For INF2 mutants, the colocalization persisted, 
leading to a broader cytoplasmic distribution of MAL.
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onset of proteinuria, 18 vs. 27 years, and of end-
stage renal disease, 21 vs. 36 years),10 although 
this needs to be verified in a larger cohort.
In conclusion, the identification of the for-
min INF2 as a crucial molecular entity in the 
occurrence of FSGS and Charcot–Marie–Tooth 
neuropathy provides additional insight into the 
role of similar cellular machinery in podocytes 
and Schwann cells, even though these two highly 
specialized cell types have distinct functions.
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Figure 4 (facing page). Effects of Disease-Causing INF2 
Mutations on the INF2–CDC42 Interaction and CDC42 
Subcellular Localization.
Panel A shows the in vivo interaction of the constitu-
tively active form of CDC42 (human influenza hemag-
glutinin [HA]-CDC42–Q61L) and FLAG-tagged wild-
type and mutant INF2 constructs in HEK-293T cells. 
The histogram shows the amount of co-immunopre-
cipitated INF2 protein normalized to the amount of 
immunoprecipitated CDC42 protein. The ratio of wild-
type FLAG-INF2 to HA-CDC42–Q61L was set to 1, and 
all other values were calculated relative to it. Panel B 
shows HeLa cells transfected with plasmids encoding 
either a wild-type or mutant FLAG-tagged INF2 (red) 
and a constitutively active HA-tagged form of CDC42 
(green). All cells expressing CDC42-Q61L alone or with 
wild-type INF2 exhibited cytoplasmic staining of CDC42, 
and about 60% also showed membrane localization. 
Mutant forms of INF2 led to a mislocalization of both 
proteins, the INF2 staining being diffuse in the cyto-
plasm and CDC42 being less targeted to the plasma 
membrane. The associated histogram represents the 
mean percentage of cells showing membrane staining 
of CDC42 (with >30 cells cotransfected per experiment). 
CMT denotes Charcot–Marie–Tooth disease, and FSGS 
focal segmental glomerulosclerosis. T bars indicate the 
standard errors for three independent experiments. IP 
denotes immunoprecipitation.
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